Dyna Colchicine Tablet 0.5mg

Country: Malasja

Lingwa: Ingliż

Sors: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Ingredjent attiv:

COLCHICINE

Disponibbli minn:

DYNAPHARM (M) SDN BHD

INN (Isem Internazzjonali):

COLCHICINE

Unitajiet fil-pakkett:

100 Tablets; 100 Tablets

Manifatturat minn:

DYNAPHARM (M) SDN BHD

Fuljett ta 'informazzjoni

Consumer Medication Information Leaflet (RiMUP)
DYNA COLCHICINE TABLET 0.5MG
Colchicine (0.5 mg)
Page 1 of 2
What is in this leaflet
1.
What DYNA COLCHICINE
TABLET 0.5MG is used for
2.
How DYNA COLCHICINE
TABLET 0.5MG works
3.
Before you use DYNA
COLCHICINE TABLET 0.5MG
4.
How to use DYNA COLCHICINE
TABLET 0.5MG
5.
While you are using it
6.
Side effects
7.
Storage and Disposal of DYNA
COLCHICINE TABLET 0.5MG
8.
Product Description
9.
Manufacturer and Product
Registration Holder
10.
Date of revision
What DYNA COLCHICINE
TABLET 0.5MG is used for
DYNA COLCHICINE TABLET
0.5MG is used for the relief of acute
gout when the dramatic response can be
diagnostic. It is also used for the
prevention of recurrent gout and to
prevent acute attacks during the first
few months of treatment with
Allopurinol or gout suppressants.
How DYNA COLCHICINE
TABLET 0.5MG works
Colchicine produces a dramatic
response in acute gout probably by
reducing the inflammatory reaction to
urate crystals. Colchicine also inhibits
cell division.
Before you use DYNA
COLCHICINE TABLET 0.5MG
-
When you must not use it
Pregnancy and lactation
Do not take DYNA COLCHICINE
TABLET 0.5MG if you are pregnant,
trying to get pregnant or think you may
be pregnant.
Do not take DYNA COLCHICINE
TABLET 0.5MG if you are breast-
feeding. Ask your doctor or pharmacist
for advice before taking any medicine.
-
Before you start use it
Tell your doctor if you have:
•
Hypersensitivity to the active
substance or to any of the
excipients.
•
Blood dyscrasias.
•
Pregnancy.
•
Breastfeeding.
•
Childbearing potential unless using
effective contraceptive measures.
•
Severe renal impairment.
•
Severe hepatic impairment.
•
Undergoing haemodialysis.
•
Renal or hepatic impairment who
are taking a P-glycoprotein (P-gp)
inhibitor or a strong CYP3A4
inhibitor.
-
Taking other medicines
Tell your doctor if you are taking any
other medicines, including any that you
buy without a prescription from a
pharmacy, supermarket or health food
shop.
Potential risk of severe drug
inter

Karatteristiċi tal-prodott

DYNA COLCHICINE TABLET 0.5MG
MAL19962516AZ
DESCRIPTION:
TABLET
Colour
:
White
Shape
:
Round/Biconvex
Coating :
Film-coated
EACH TABLET CONTAINS: Colchicine ..................... 0.5 mg
PHARMACODYNAMICS:
Colchicine produces a dramatic response in acute gout probably by
reducing the inflammatory reaction to urate crystals; this
effect might be due to several actions including decreased leucocyte
mobility. It is not an analgesic and has no effect on
blood concentrations of Uric Acid, or on the excretion of Uric Acid.
Colchicine also has an antimitotic action.
PHARMACOKINETICS:
Colchicine is readily absorbed from the gastrointestinal tract and
reaches peak concentration in the plasma within 2 hours. It
is partially deacetylated in the liver and the unchanged drug and its
metabolites are excreted in the bile and undergo
intestinal reabsorption. Colchicine is found in high concentrations in
leucocytes, kidneys, the liver, and spleen. Most of the
drug is excreted in the faeces but 10 to 20% is excreted in the urine
and this proportion rises in patients with liver disorders.
INDICATION:
It is used for the relief of acute gout when the dramatic response can
be diagnostic. It is also used for the prophylaxis of
recurrent gout and to prevent acute attacks during the first few
months of treatment with Allopurinol or uricosurics.
RECOMMENDED DOSE:
Treatment of acute gout attack:
1 mg (2 tablets) to start followed by 500 micrograms (1 tablet) after
1 hour.
No further tablets should be taken for 12 hours.
After 12 hours, treatment can resume if necessary with a maximum dose
of 500 micrograms (1 tablet) every 8 hours until
symptoms are relieved.
The course of treatment should end when symptoms are relieved or when
a total of 6 mg (12 tablets) has been taken.
No more than 6 mg (12 tablets) should be taken as a course of
treatment.
After completion of a course, another course should not be started for
at least 3 days (72 hours).
Prophylaxis of gout attack during initiation of therapy with
allopurinol and uricosuric drugs:
500 micr